Waters UHPLC Systems Purchased for Metabolomics Research

April 15, 2009

Waters Corporation (Milford, Massachusetts) announced that the National Cancer Institute?s Center for Cancer Research (Bethesda, Maryland) has purchased the company?s ACQUITY UPLC?Synapt High Definition mass spectrometry (MS) and ACQUITY UPLC?Xevo TQ MS systems for metabolomics research programs.

Waters Corporation (Milford, Massachusetts) announced that the National Cancer Institute’s Center for Cancer Research (Bethesda, Maryland) has purchased the company’s ACQUITY UPLC–Synapt High Definition mass spectrometry (MS) and ACQUITY UPLC–Xevo TQ MS systems for metabolomics research programs. The research is intended to discover small molecule metabolites or biomarkers associated with cancer susceptibility and diagnosis, treatment efficacy, and adverse effects of medicines and other chemicals. The research requires sensitive analytical instrumentation capable of analyzing thousands of samples per month.